[Testis cancer: the UK as a model]
- PMID: 19352606
- DOI: 10.1007/s00120-009-1949-9
[Testis cancer: the UK as a model]
Abstract
Over the course of the past 30 years progress in identification of risk factors, improvements in therapy regimens and advances in treatment delivery have all served to render testis cancer a treatable and survivable malignancy. Institution of specialised oncology centres in the UK to address treatment options for urological cancers has proven to be an effective approach to managing testis cancer by drawing on interdisciplinary expertise and applying insights gained from ongoing R&D. This strategy could become a model for treating other cancers as well.
Similar articles
-
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies.Urol Oncol. 2009 Mar-Apr;27(2):122-5. doi: 10.1016/j.urolonc.2008.10.008. Urol Oncol. 2009. PMID: 19285223 No abstract available.
-
Urological oncology in Europe. Research highlights from the XVIIth congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002.Drugs Today (Barc). 2002 Apr;38(4):221-34. Drugs Today (Barc). 2002. PMID: 12532191 No abstract available.
-
Urological Oncology: Testis Cancer and Advances in Oncologic Therapy.J Urol. 2022 Apr;207(4):931. doi: 10.1097/JU.0000000000002407. Epub 2022 Jan 7. J Urol. 2022. PMID: 34991329 No abstract available.
-
[Management of pediatric testicular tumors : diagnosis, therapy, and follow-up].Urologe A. 2009 Apr;48(4):359-63. doi: 10.1007/s00120-009-1944-1. Urologe A. 2009. PMID: 19280171 Review. German.
-
Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients.Onkologie. 2011;34(1-2):59-64. doi: 10.1159/000323346. Epub 2011 Jan 17. Onkologie. 2011. PMID: 21346388 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous